PUBLIKATIONER
Cornillet M, Villard C, Rorsman F, Molinaro A, Nilsson E, Kechagias S, Von Seth E, Bergquist A. The Swedish initiative for the study of Primary sclerosing cholangitis (SUPRIM). EClinicalMedicine. 2024;70:102526. PubMed PDF
Villard C, Friis-Liby I, Rorsman F, Said K, Warnqvist A, Cornillet M, Kechagias S, Nyhlin N, Werner M, Janczewska I, Hagström T, Nilsson E, Bergquist A. Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis. J Hepatol. 2023;78(3): 604-613. PubMed PDF
Henriksson I, Udumyan R, Nilsson E, Önnerhag K, Rorsman F, Werner M, Marschall HU, Wahlin S, Nyhlin N. Clinical outcomes and sick leave in relation to UDCA treatment in Swedish patients with primary biliary cholangitis. Scand J Gastroenterol. 2022;21:1-6. PubMed PDF
Bergquist A, Marschall HU, Nilsson E, Nyhlin N, Werner M, Klein A, Bottai M, Kerchagias S, Rorsman F. Long Term Effect of Simvastatin in Primary Sclerosing Cholangitis: A Placebo-Controlled, Double-Blind, Multicenter Phase III study. Br J Gastroenterol 2022;4(1):235-241. PDF
Hagström H, Ndegwa N, Jalmeus M, Ekstedt M, Posserud I, Rorsman F, Nyhlin N, Klintman D, Werner M, Marschall H-U, Askling J, Stål P. Morbidity, risk of cancer and mortality in 3645 HFE mutation carriers. Liver Int. 2021; 00:1-9. PubMed PDF
Giannakopoulos G, Verbaan H, Friis-Liby I, Sangfelt P, Nyhlin N, Almer S; Swedish Hepatology study group, SweHep. Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine. Dig Liver Dis 2019; 51(2):253-257. PubMed
Hagström H, Nasr P, Ekstedt M, Kechagias S, Önnerhag K, Nilsson E, Rorsman F, et al. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol 2017;52:159-165. PubMed PDF
Danielsson Borssén Å, Marschall HU, Bergquist A, Rorsman F, Weiland O, Kechagias S, Nyhlin N, et al. Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. Scand J Gastroenterol 2017;52:1022-1028. PubMed PDF
Danielsson Borssén Å, Palmqvist R, Kechagias S, Marschall HU, Bergquist A, Rorsman F, Weiland O, et al. Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis: A cohort study. Medicine (Baltimore) 2017;96:e7708. PubMed PDF
Stål P, Friis-Liby I. Leversjukdom med akut försämring kräver omedelbar handläggning. Läkartidningen 2016;113. Länk
Wahlin S. Hepatisk encefalopati - det akuta omhändertagandet. Läkartidningen 2016;113. PDF
Verbaan H, Sangfelt P. Akut njursvikt är en vanlig komplikation vid levercirros - handlägg proaktivt för att förhindra ytterligare försämrad njurfunktion. Läkartidningen 2016;113. PDF
Stål P, Oksanen A. Akut-på-kronisk leversvikt är en egen klinisk entitet - leder till svikt i ett eller flera organ. Läkartidningen 2016;113. PDF
Schult A, Friis-Liby I. Ascites orsakas oftast av bakomliggande levercirros - saltrestriktion och diuretika är grundval för behandlingen. Läkartidningen 2016;113. PDF
Rajani R, Marschall HU. Blödning och trombos - akuta komplikationer vid levercirros. Läkartidningen 2016;113. PDF
Hagström H, Rorsman F. Infektioner vanliga vid akut och kronisk leversjukdom. Läkartidningen 2016;113. PDF
Danielsson Borssén Å, Wallerstedt S, Nyhlin N, Bergquist A, Lindgren S, Almer S, Werner M. Pregnancy and childbirth in women with autoimmune hepatitis is safe, even in compensated cirrhosis. Scand J Gastroenterol 2016;51:479-485. PubMed PDF
Danielsson Borssén Å, Almer S, Prytz H, Wallerstedt S, Friis-Liby IL, Bergquist A, Nyhlin N, et al. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis-a long-term follow-up study in 634 Swedish patients. Scand J Gastroenterol 2015;50:217-223. PubMed PDF
Chaireti R, Rajani R, Bergquist A, Melin T, Friis-Liby IL, Kapraali M, Kechagias S, et al. Increased thrombin generation in splanchnic vein thrombosis is related to the presence of liver cirrhosis and not to the thrombotic event. Thromb Res 2014;134:455-461. PubMed PDF
Wallerstedt S, Simrén M, Wahlin S, Lööf L, Hultcrantz R, Sjöberg K, Sandberg-Gertzén H, et al. Moderate hyperkalemia in hospitalized patients with cirrhotic ascites indicates a poor prognosis. Scand J Gastroenterol 2013;48:358-365. PubMed PDF
Magnusson M, Sten-Linder M, Bergquist A, Rajani R, Kechagias S, Fischler B, Nemeth A, et al. The international normalized ratio according to Owren in liver disease: interlaboratory assessment and determination of international sensitivity index. Thromb Res 2013;132:346-351. PubMed
Lindström L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013;11:841-846. PubMed PDF
Lindström L, Boberg KM, Wikman O, Friis-Liby I, Hultcrantz R, Prytz H, Sandberg-Gertzén H, et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther 2012;35:451-457. PubMed PDF
Kechagias S, Ekstedt M. Icke-alkoholorsakad fettleversjukdom kan ge permanent leverskada. Läkartidningen 2012;109:2100-2104. PDF
Stål P, Hultcrantz R. Hereditär hemokromatos - en vanlig genetisk sjukdom. Läkartidningen 2012;109:2097-2099. PDF
Prytz H, Lindgren S. Ovanliga metabola sjukdomar kan visa sig som leversjukdom. Läkartidningen 2012;109:2090-2092. PDF
Hultcrantz R, Agreus L. Övervikt och läkemedelsbiverkan vanligast vid förhöjda levervärden. Läkartidningen 2012;109:2088-2089. PDF
Hultcrantz R. Metabol leversjukdom är ofta orsaken. Läkartidningen 2012;109:2087. PDF
Friis-Liby I, Wallerstedt S, Marschall HU. Ikterus och kolestas. Läkartidningen 2012;109:2093-2096. PDF
Aleman S, Endalib S, Stål P, Lööf L, Lindgren S, Sandberg-Gertzén H, Almer S, et al. Health check-ups and family screening allow detection of hereditary hemochromatosis with less advanced liver fibrosis and survival comparable with the general population. Scand J Gastroenterol 2011;46:1118-1126. PubMed
Werner M, Wallerstedt S, Lindgren S, Almer S, Björnsson E, Bergquist A, Prytz H, et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol 2010;45:457-467. PubMed
Rajani R, Björnsson E, Bergquist A, Danielsson Å, Gustavsson A, Grip O, Melin T, et al. The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Aliment Pharmacol Ther 2010;32:1154-1162. PubMed PDF
Hindorf U, Jahed K, Bergquist A, Verbaan H, Prytz H, Wallerstedt S, Werner M, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010;52:106-111. PubMed
Werner M, Danielsson Å. Autoimmun hepatit kräver ofta livslång behandling. Läkartidningen 2010;107:1388-1391. PDF
Lööf L, Lindgren S. Primär biliär cirros har god prognos när symtom saknas. Läkartidningen 2010;107:1396-1398. PDF
Lindgren S. Sjukdomarna överlappar ofta varandra. Läkartidningen 2010;107:1399-1400. PDF
Glaumann H. Leverbiopsi överlägsen diagnosmetod... i vissa fall. Läkartidningen 2010;107:1385-1387. PDF
Dahle C. Autoantikroppar centrala för diagnos. Läkartidningen 2010;107:1379-1381. PDF
Bergquist A, Prytz H, Björnsson E. Svårt bromsa primär skleroserande kolangit. Läkartidningen 2010;107:1392-1395. PDF
Albiin N. Levern i bild - diagnostik i dag och i morgon. Läkartidningen 2010;107:1382-1384. PDF
Lindgren S, Danielsson Å. Leversjukdomar i fokus för svensk forskning. Läkartidningen 2010;107:1378. PDF
Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Björnsson E, Bergquist A, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 2009;50:388-393. PubMed
Rajani R, Melin T, Björnsson E, Broomé U, Sangfelt P, Danielsson Å, Gustavsson A, et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience. Liver Int 2009;29:253-259. PubMed
Olsson R, Glaumann H, Almer S, Broomé U, Lebrun B, Bergquist A, Björnsson E, et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009;20:190-196. PubMed
Lindgren S, Glaumann H, Almer S, Bergquist A, Björnsson E, Broomé U, Danielsson Å, et al. Transitions between variant forms of primary biliary cirrhosis during long-term follow-up. Eur J Intern Med 2009;20:398-402. PubMed
Elmberg M, Hultcrantz R, Ebrahim F, Olsson S, Lindgren S, Lööf L, Stål P, et al. Increased mortality risk in patients with phenotypic hereditary hemochromatosis but not in their first-degree relatives. Gastroenterology 2009;137:1301-1309. PubMed
Werner M, Prytz H, Ohlsson B, Almer S, Björnsson E, Bergquist A, Wallerstedt S, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008;43:1232-1240. PubMed
Björnsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, Boberg KM, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008;134:975-980. PubMed
Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson Å, Lindgren S, Prytz H, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008;6:939-943. PubMed
Werner M, Björnsson E, Prytz H, Lindgren S, Almer S, Broomé U, Wallerstedt S, et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007;42:986-991. PubMed
Wei G, Bergquist A, Broomé U, Lindgren S, Wallerstedt S, Almer S, Sangfelt P, et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med 2007;262:393-401. PubMed PDF
Wallerstedt S, Olsson R, Simrén M, Broomé U, Wahlin S, Lööf L, Hultcrantz R, et al. Abdominal tenderness in ascites patients indicates spontaneous bacterial peritonitis. Eur J Intern Med 2007;18:44-47. PubMed
Björnsson E, Wei G, Bergquist A, Broomé U, Wallerstedt S, Almer S, Sangfelt P, et al. Akut leversvikt - viktigt med snabb multidisciplinär handläggning. Läkartidningen 2007;104:210-213. PDF
Prytz H, Keiding S, Björnsson E, Broomé U, Almer S, Castedal M, Munk OL, et al. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 2006;44:1572-1580. PubMed
Nyblom H, Björnsson E, Simrén M, Aldenborg F, Almer S, Olsson R. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int 2006;26:840-845. PubMed
Bergquist A, Montgomery SM, Lund U, Ekbom A, Olsson R, Lindgren S, Prytz H, et al. Perinatal events and the risk of developing primary sclerosing cholangitis. World J Gastroenterol 2006;12:6037-6040. PubMed PDF
Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-1472. PubMed
Ormarsdóttir S, Mallmin H, Naessén T, Petrén-Mallmin M, Broomé U, Hultcrantz R, Lööf L. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med 2004;256:63-69. PubMed PDF
Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, Lindgren S, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003;125:1733-1741. PubMed
Wassmuth R, Depner F, Danielsson Å, Hultcrantz R, Lööf L, Olson R, Prytz H, et al. HLA class II markers and clinical heterogeneity in Swedish patients with primary biliary cirrhosis. Tissue Antigens 2002;59:381-387. PubMed
Ormarsdóttir S, Ljunggren Ö, Mallmin H, Olsson R, Prytz H, Lööf L. Longitudinal bone loss in postmenopausal women with primary biliary cirrhosis and well-preserved liver function. J Intern Med 2002;252:537-541. PubMed PDF
Broomé U, Glaumann H, Lindström E, Lööf L, Almer S, Prytz H, Sandberg-Gertzén H, et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002;36:586-589. PubMed
Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson Å, Hultcrantz R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-327. PubMed
Lindgren S, Nilsson S, Nässberger L, Verbaan H, Wieslander J. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK). J Gastroenterol Hepatol 2000;15:437-442. PubMed
Olsson R, Broomé U, Danielsson Å, Hägerstrand I, Järnerot G, Lööf L, Prytz H, et al. Spontaneous course of symptoms in primary sclerosing cholangitis: relationships with biochemical and histological features. Hepatogastroenterology 1999;46:136-141. PubMed
Hultcrantz R, Olsson R, Danielsson Å, Järnerot G, Lööf L, Rydén B-O, Wahren B, et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999;30:669-673. PubMed
Sjöberg K, Lindgren S, Eriksson S. Frequent occurrence of non-specific gliadin antibodies in chronic liver disease. Endomysial but not gliadin antibodies predict coeliac disease in patients with chronic liver disease. Scand J Gastroenterol 1997;32:1162-1167. PubMed
Lindgren S, Braun HB, Michel G, Nemeth A, Nilsson S, Thome-Kromer B, Eriksson S. Absence of LKM-1 antibody reactivity in autoimmune and hepatitis-C-related chronic liver disease in Sweden. Swedish Internal Medicine Liver club. Scand J Gastroenterol 1997;32:175-178. PubMed
Eriksson LS, Olsson R, Glauman H, Prytz H, Befrits R, Rydén B-O, Einarsson K, et al. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. Scand J Gastroenterol 1997;32:179-186. PubMed
Janczewska I, Olsson R, Hultcrantz R, Broomé U. Pregnancy in patients with primary sclerosing cholangitis. Liver 1996;16:326-330. PubMed
Broomé U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson Å, Prytz H, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-615. PubMed PDF
Olsson R, Hägerstrand I, Broomé U, Danielsson Å, Järnerot G, Lööf L, Prytz H, et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 1995;48:933-935. PubMed PDF
Olsson R, Broomé U, Danielsson Å, Hägerstrand I, Järnerot G, Lööf L, Prytz H, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995;108:1199-1203. PubMed
Olsson R, Broomé U, Danielsson Å, Hägerstrand I, Järnerot G, Lööf L, Prytz H, et al.: Colchicine treatment and prognostic value of cholangiography in primary sclerosing cholangitis. In: van Berge Henegouwen GP, van Hook B, de Groote J, Matern S, Stockbrügger RW, eds. Cholestatic Liver diseases. Dordrecht, Netherlands: Kluwer Academic Publisher, 1994; 255-261.
Lööf L, Adami H-O, Sparén P, Danielsson Å, Eriksson LS, Hultcrantz R, Lindgren S, et al. Cancer risk in primary biliary cirrhosis: a population-based study from Sweden. Hepatology 1994;20:101-104. PubMed
Olsson R, Lööf L, Wallerstedt S. Pregnancy in patients with primary biliary cirrhosis--a case for dissuasion? The Swedish Internal Medicine Liver Club. Liver 1993;13:316-318. PubMed
Lindgren S, Danielsson Å, Olsson R, Prytz H, Eriksson S. Prednimustin treatment in primary biliary cirrhosis: a preliminary study. J Intern Med 1992;231:139-141. PubMed
Olsson R, Danielsson Å, Järnerot G, Lindström E, Lööf L, Rolny P, Rydén B-O, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319-1323. PubMed
Olsson R, Lindberg J, Weiland O, Nilsson L. Chronic active hepatitis in Sweden. The etiologic spectrum, clinical presentation, and laboratory profile. Scand J Gastroenterol 1988;23:463-470. PubMed
Copyright SweHep